title: Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.
abstract: Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.
authors: Princess Margaret Hospital, Toronto, ON;
authors: Jo-An
authors: JA
authors: Seah
authors: Normand
authors: N
authors: Blais
authors: Scott
authors: S
authors: North
authors: Yasmin
authors: Y
authors: Rahim
authors: Dean
authors: D
authors: Ruether
authors: Peter C
authors: PC
authors: Black
authors: Alexandre R
authors: AR
authors: Zlotta
authors: Lori
authors: L
authors: Wood
authors: Srikala S
authors: SS
authors: Sridhar